Skip to content
AnalystLens

Teva Pharmaceutical Industries 8-K Report, Financial Results (Jul 30, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 30, 2025
Period End
July 30, 2025
Security
TEVA
In the record · 2016–202610-K1110-Q278-K283

TEVA filed 11 annual reports (10-K), 27 quarterly reports (10-Q) and 283 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Nov ’19Nov ’19
  2. Leadership change8-K · Nov ’22Nov ’22
  3. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) reported its second-quarter 2025 results on July 30, 2025 (Exhibit 99.1, a press release, furnished under Item 2.02).

Revenues were $4,176 milliona, flat in U.S. dollars and down 1% in local currency. GAAP net income attributable to Teva was $282 million, or $0.24 per diluted share, and non-GAAP diluted EPS was $0.66, up $0.05 year-over-year. Operating income was $455 million, and non-GAAP operating income was $1,133 million, a non-GAAP operating margin of 27.1%.

Operating cash flow was $227 millionb and free cash flow was $476 million. Teva said its key innovative products (AUSTEDO, AJOVY and UZEDY) grew about 26% in local currency and raised their 2025 revenue outlook, while the generics business was described as stable. The company raised its 2025 outlook for AUSTEDO to $2,000-2,050 million, AJOVY to $630-640 million and UZEDY to $190-200 million, and its non-GAAP diluted EPS outlook to $2.50-2.65 (up $0.05 at the low end).

It reaffirmed revenues of $16.8c-17.2 billion, non-GAAP operating income of $4.3-4.6 billion, adjusted EBITDA of $4.7-5.0 billion and free cash flow of $1.6-1.9 billion. The revised outlook excludes the Japan business venture after Q1 and the expected Sanofi milestone payments tied to duvakitug, and it does not reflect possible pharmaceutical tariffs. The company is pursuing its Pivot to Growth strategy and targets a 30% operating margin by 2027.

Its Teva Transformation programs are expected to deliver about $700 milliond of net savings through 2027, including about $70 million in 2025. Teva is also working to sell its API business, which it classified as held for sale on December 31, 2024, and total debt was $17,227 million as of June 30, 2025, down from $17,783 million at December 31, 2024.

02—Key points

Key Highlights

  1. Q2 2025 revenues of $4,176 million, flat in U.S. dollars and down 1% in local currency; described as the tenth consecutive quarter of year-over-year revenue growth in the release headline
  2. GAAP diluted EPS of $0.24 versus a loss of $0.75 in Q2 2024; non-GAAP diluted EPS of $0.66, up from $0.61
  3. Non-GAAP operating income of $1,133 million (27.1% margin) versus $1,056 million (25.3%) a year earlier; operating income of $455 million versus an operating loss of $5 million
  4. Free cash flow of $476 million, up from $324 million; operating cash flow of $227 million
  5. Raised 2025 outlook for AUSTEDO ($2,000-2,050 million), AJOVY ($630-640 million), UZEDY ($190-200 million) and non-GAAP diluted EPS ($2.50-2.65); other guidance components reaffirmed
  6. Debt reduced to $17,227 million from $17,783 million at December 31, 2024, after $2,290 million of notes repurchased in a tender offer and $2,305 million of senior notes issued
  7. Ongoing sale of the API business, held for sale since December 31, 2024, with no definitive agreement stated as of the filing

03—Questions

Frequently Asked Questions

  1. Why did Teva raise its 2025 outlook?

    Teva raised the 2025 revenue outlook for its key innovative products: AUSTEDO to $2,000-2,050 million, AJOVY to $630-640 million and UZEDY to $190-200 million. It also raised the low end of its non-GAAP diluted EPS outlook by $0.05 to $2.50-2.65. The filing states these key innovative products grew about 26% in local currency in Q2 2025.

  2. How did the generics business perform?

    The release describes generics as stable. Global generics fell 2% in local currency excluding Japan BV, with U.S. generic product revenues down 6%, Europe up 1% and International Markets down 1%, all in local currency and excluding Japan BV revenues. U.S. generic revenues were $961 million, lower mainly due to lenalidomide capsules and liraglutide injection.

  3. What changed in Teva's outlook for revenues and profit?

    Revenue guidance of $16.8-17.2 billion, non-GAAP operating income of $4.3-4.6 billion and adjusted EBITDA of $4.7-5.0 billion were reaffirmed. The revised outlook excludes the Japan business venture after Q1 and the expected Sanofi development milestone payments tied to duvakitug, and it is based on the tariff environment as of July 30, 2025.

  4. What is the status of the API business sale and cost savings program?

    Teva is engaged with prospective purchasers for its API business, but a sale remains contingent on reaching a definitive agreement and Board approval. The Teva Transformation programs are expected to deliver about $700 million of net savings through 2027, with about $70 million expected in 2025 and about $140 million on a full-year run-rate basis.

04—Continue

← View all 8-K filings